INS and Insulin resistance: Our results indicate that co‐treatment with metformin can counteract consequences of rapamycin‐driven hepatic insulin resistance and protect pancreatic islets from aspects of rapamycin‐driven pancreatic impairment while sustaining potentially beneficial reduction of circulating levels of insulin.